ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INSHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES

DE602021051081T2Active Publication Date: 2026-04-01KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
0 Cites 0 Cited by

Patent Information

Application Number
DE602021051081
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-02-11
Filing Date
2021-02-10
Publication Date
2026-04-01
Estimated Expiration
2041-02-10

AI Technical Summary

Technical Problem

Current therapies for preventing neointimal hyperplasia and restenosis, such as mTOR inhibitor-coated stents, are non-specific and pose safety concerns, while neointimal hyperplasia is characterized by smooth muscle cell migration and proliferation, necessitating a targeted and safer alternative.

Method used

A medical device comprising a TRPC6 inhibitor for localized administration to inhibit smooth muscle cell migration, using catheters, stents, balloons, or bioabsorbable scaffolds to target neointimal hyperplasia and restenosis.

Benefits of technology

TRPC6 inhibitors effectively reduce smooth muscle cell migration, thereby minimizing neointimal hyperplasia and restenosis risk with lower side effects compared to mTOR inhibitors, maintaining vascular patency and reducing thrombosis concerns.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.